公开(公告)号：US20230285274A1

公开(公告)日：2023-09-14

申请号：US18177875

申请日：2023-03-03

申请人： The Foundry, LLC

发明人： Mark E. Deem ,  Hanson Gifford

IPC分类号： A61K9/00 ,  A61K38/16 ,  A61K38/48 ,  A61K41/00 ,  A61N1/32 ,  A61N1/08 ,  A61N1/30 ,  A61N7/00 ,  A61B18/14 ,  A61B18/18 ,  A61N5/10 ,  A61M37/00

CPC分类号： A61K9/0021 ,  A61K38/164 ,  A61K38/168 ,  A61K38/4893 ,  A61K41/00 ,  A61K41/0028 ,  A61N1/327 ,  A61K9/0078 ,  A61N1/08 ,  A61N1/303 ,  A61N7/00 ,  A61B18/1492 ,  A61B18/1815 ,  A61N5/10 ,  A61K41/0047 ,  A61M37/00 ,  A61M37/0092 ,  C12Y304/24069 ,  Y02A50/30 ,  A61B2018/0016

摘要： Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.

公开(公告)号：US11679077B2

公开(公告)日：2023-06-20

申请号：US17151938

申请日：2021-01-19

申请人： The Foundry, LLC

发明人： Mark E. Deem ,  Hanson Gifford

IPC分类号： C12M1/00 ,  A61K9/00 ,  A61K38/16 ,  A61K38/48 ,  A61K41/00 ,  A61N1/32 ,  A61N1/08 ,  A61N1/30 ,  A61N7/00 ,  A61B18/14 ,  A61B18/18 ,  A61N5/10 ,  A61M37/00 ,  A61B18/00

CPC分类号： A61K9/0021 ,  A61B18/1492 ,  A61B18/1815 ,  A61K9/0078 ,  A61K38/164 ,  A61K38/168 ,  A61K38/4893 ,  A61K41/00 ,  A61K41/0028 ,  A61K41/0047 ,  A61M37/00 ,  A61M37/0092 ,  A61N1/08 ,  A61N1/303 ,  A61N1/327 ,  A61N5/10 ,  A61N7/00 ,  C12Y304/24069 ,  A61B2018/0016 ,  A61B2018/00214 ,  A61B2018/00434 ,  A61B2018/1861 ,  A61M2210/1035 ,  A61N2007/003 ,  Y02A50/30 ,  A61K38/4893 ,  A61K2300/00

摘要： Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.

公开(公告)号：US11666526B2

公开(公告)日：2023-06-06

申请号：US16984528

申请日：2020-08-04

申请人： The Foundry, LLC

发明人： Mark E. Deem ,  Hanson Gifford

IPC分类号： C12M1/00 ,  A61K9/00 ,  A61K38/16 ,  A61K38/48 ,  A61K41/00 ,  A61N1/32 ,  A61N1/08 ,  A61N1/30 ,  A61N7/00 ,  A61B18/14 ,  A61B18/18 ,  A61N5/10 ,  A61M37/00 ,  A61B18/00

CPC分类号： A61K9/0021 ,  A61B18/1492 ,  A61B18/1815 ,  A61K9/0078 ,  A61K38/164 ,  A61K38/168 ,  A61K38/4893 ,  A61K41/00 ,  A61K41/0028 ,  A61K41/0047 ,  A61M37/00 ,  A61M37/0092 ,  A61N1/08 ,  A61N1/303 ,  A61N1/327 ,  A61N5/10 ,  A61N7/00 ,  C12Y304/24069 ,  A61B2018/0016 ,  A61B2018/00214 ,  A61B2018/00434 ,  A61B2018/1861 ,  A61M2210/1035 ,  A61N2007/003 ,  Y02A50/30 ,  A61K38/4893 ,  A61K2300/00

摘要： Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.

公开(公告)号：US11517360B2

公开(公告)日：2022-12-06

申请号：US15864796

申请日：2018-01-08

申请人： The Foundry, LLC

发明人： Vivek Shenoy ,  Mark Deem

IPC分类号： A61F2/08 ,  A61B17/56 ,  A61B17/80

摘要： Prostheses and methods for treating canine cruciate ligament disease are disclosed comprising placement of a specifically configured implant on the femur or tibia to displace targeted muscle or connective tissue associated with the stifle joint so as to reduce cranial tibial thrust.

公开(公告)号：US20220183865A1

公开(公告)日：2022-06-16

申请号：US17593996

申请日：2020-04-01

申请人： The Foundry, LLC

发明人： Hanson S. Gifford, III ,  Adam Gold

IPC分类号： A61F2/90

摘要： The present technology relates to devices for treating arteries. In several embodiments, for example, the present technology comprises an expandable structure configured to be intravascularly positioned within a lumen of the artery at a treatment site, where the artery has a substantially circular cross-sectional shape at the treatment site prior to deployment of the expandable structure therein. When the expandable structure is in an expanded state and positioned in apposition with the arterial wall at the treatment site under diastolic pressure, the expandable structure may force the artery into a non-circular cross-sectional shape. A cross-sectional area of the artery in the non-circular cross-sectional shape may be less than a cross-sectional area of the artery in the substantially circular cross-sectional shape.

公开(公告)号：US20210308433A1

公开(公告)日：2021-10-07

申请号：US17250607

申请日：2019-08-09

申请人： Hanson S. Gifford, III ,  Edward DeWitt Gifford ,  The Foundry, LLC

发明人： Hanson S. Gifford, III ,  Edward DeWitt Gifford ,  Vrad W. Levering

IPC分类号： A61M25/10

摘要： Devices, systems, and methods for treating a blood flow passage are discloses herein. In one example, a treatment device includes an expandable element configured to be positioned within the passage and a reinforcing element. The expandable element may have an expanded configuration in which the expandable element defines a lumen therethrough. The reinforcing element may be positioned within the lumen of the expandable element. The reinforcing element may be coupled to the expandable element such that expansion of the expandable element causes the reinforcing element to radially expand, thereby creating a perfusion lumen through the device.

公开(公告)号：US20180264092A1

公开(公告)日：2018-09-20

申请号：US15988801

申请日：2018-05-24

申请人： The Foundry, LLC

发明人： John MORRISS ,  Cary REICH ,  Hanson GIFFORD

IPC分类号： A61K38/48 ,  A61K9/12 ,  A61K9/00 ,  A61M31/00

CPC分类号： A61K38/4893 ,  A61K9/0043 ,  A61K9/122 ,  A61M31/00 ,  C12Y304/24069

摘要： A system for delivering a therapeutic agent to a nasopharyngeal mucosa target comprises a foam generating mechanism, a gas, a therapeutic agent in liquid form that inhibits mucus production, and a delivery device. Actuation of the foam generating mechanism entraps gaseous bubbles from the gas in the liquid thereby forming a foam. The therapeutic agent is dispersed in the foam which has an expanded configuration adapted to fill a nasopharyngeal space and deliver the therapeutic agent to the mucosa targets. The delivery device is for delivering the foam to the nasopharyngeal space. The foam may also have a collapsed configuration for removal from the nasopharyngeal space or for concentration of the therapeutic agent onto the mucosa.

公开(公告)号：US10022529B2

公开(公告)日：2018-07-17

申请号：US15358187

申请日：2016-11-22

申请人： The Foundry, LLC

发明人： Mark E. Deem ,  Hanson S. Gifford, III

IPC分类号： C12M1/00 ,  A61M37/00 ,  A61K38/16 ,  A61K38/48 ,  A61K41/00 ,  A61N1/08 ,  A61N1/32 ,  A61N1/30 ,  A61N7/00 ,  A61K9/00 ,  A61B18/14 ,  A61B18/18 ,  A61N5/10 ,  A61B18/00

摘要： Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.

公开(公告)号：US20180055541A1

公开(公告)日：2018-03-01

申请号：US15790619

申请日：2017-10-23

申请人： The Foundry, LLC

发明人： Vivek Shenoy ,  Mark Deem ,  Hanson S. Gifford, III

IPC分类号： A61B17/56

CPC分类号： A61B17/56 ,  A61B2017/564 ,  A61B2017/565

摘要： Pathologies of joints arising from improper force distributions are addressed by displacement of targeted connective and muscle tissues surrounding the joint in order to realign force vectors and alter moment arms loading the joint.

公开(公告)号：US20180021555A1

公开(公告)日：2018-01-25

申请号：US15679243

申请日：2017-08-17

申请人： The Foundry, LLC

发明人： John MORRISS ,  Hanson GIFFORD

IPC分类号： A61M31/00 ,  A61M15/08 ,  A61K38/48 ,  A61M11/00 ,  A61M16/04 ,  A61M5/32 ,  A61M11/06

CPC分类号： A61M31/007 ,  A61K38/4893 ,  A61M5/329 ,  A61M11/001 ,  A61M11/007 ,  A61M11/06 ,  A61M15/08 ,  A61M15/085 ,  A61M16/0438 ,  A61M16/0456 ,  A61M16/0461 ,  A61M16/0481 ,  A61M31/002 ,  A61M2210/0618 ,  A61M2210/0681

摘要： A system for delivering a therapeutic agent to nasopharyngeal mucosa tissue has a shaft, a porous pad of compliant material coupled to the shaft near the distal end, and a drug reservoir. The porous pad is configured to expand from a contracted configuration to an expanded configuration. The expanded configuration is adapted to engage and conform to the mucosa tissue in a nasal cavity, and the contracted configuration has a size suitable for introduction into the nasal cavity. The drug reservoir holds a therapeutic agent and is at least partially covered by the porous pad. The drug reservoir is configured to release a fixed volume of the therapeutic agent into the porous pad within a period of less than about 120 minutes, and has a wall with a plurality of channels fluidly coupled with the porous pad.